Vascular, Cardiac and Renal Target Organ Damage Associated to Arterial Hypertension: Which Noninvasive Tools for Detection?

Overview

Journal J Hum Hypertens

Specialty Cardiology & Vascular Diseases

Date 2020 Feb 12

PMID 32042074

Citations 10

Authors

Francesca Cortese

Annagrazia Cecere

Anna Maria Cortese

Andrea Andriani

Luigi Truncellito

Federica Valente

Paola Giordano

Marco Matteo Ciccone

Affiliations

Soon will be listed here.

Abstract

Arterial hypertension is a systemic condition characterized by elevated blood pressure in the vascular system. Despite the great effort of scientific community to sensitize population to the problem, enforcing the preventive and treatment measures, this condition continues to be responsible for a large portion of global mortality, as it represents one of the major modifiable risk factors of cardiovascular disease. The significant and substantial clinical implications of high blood pressure on cardiovascular morbidity and mortality are explained by the effect of hypertension on specific organs, particularly sensitive to the effects of changes in blood pressure, resulting cardiac remodeling, cerebrovascular disease, renal failure, atherosclerotic vascular disease, and retinopathy, hence the term "target organ damage". The aim of this review is to give an overview of several noninvasive tools useful in the detection of organ damage related to arterial hypertension.

Citing Articles

The relation between body mass index and target organ damage and the mediating role of blood pressure.

Papassotiriou I, Spiliopoulou S, Dragonas D, Tsoutsoura N, Korompoki E, Manios E Eur J Clin Nutr. 2025; .

PMID: 40011661 DOI: 10.1038/s41430-025-01573-6.

Nomogram for predicting risk of mild renal dysfunction among general residents from rural Northeast China.

Yu S, Yang H, Wang B, Guo X, Li G, Sun Y J Transl Int Med. 2024; 12(3):244-252.

PMID: 39081277 PMC: 11284527. DOI: 10.2478/jtim-2023-0003.

Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies.

Das D, Shruthi N, Banerjee A, Jothimani G, Duttaroy A, Pathak S Front Nutr. 2023; 10:1221438.

PMID: 37614749 PMC: 10442661. DOI: 10.3389/fnut.2023.1221438.

Based on network pharmacology, gastrodin attenuates hypertension-induced vascular smooth muscle cell proliferation and PI3K/AKT pathway activation.

Shen A, Wu M, Ali F, Guo Z, Fang Y, Zhou Y Sci Rep. 2023; 13(1):12140.

PMID: 37495624 PMC: 10372005. DOI: 10.1038/s41598-023-39202-6.

Loss of IP3R-BK Coupling Is Involved in Vascular Remodeling in Spontaneously Hypertensive Rats.

Niloy S, Shen Y, Guo L, ORourke S, Sun C Int J Mol Sci. 2023; 24(13).

PMID: 37446080 PMC: 10341547. DOI: 10.3390/ijms241310903.

References

Forouzanfar M, Liu P, Roth G, Ng M, Biryukov S, Marczak L . Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017; 317(2):165-182. DOI: 10.1001/jama.2016.19043. View

Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah A, Denaxas S . Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014; 383(9932):1899-911. PMC: 4042017. DOI: 10.1016/S0140-6736(14)60685-1. View

Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28):2159-219. DOI: 10.1093/eurheartj/eht151. View

Wright Jr J, Williamson J, Whelton P, Snyder J, Sink K, Rocco M . A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373(22):2103-16. PMC: 4689591. DOI: 10.1056/NEJMoa1511939. View

Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T . Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2015; 387(10017):435-43. DOI: 10.1016/S0140-6736(15)00805-3. View

Ettehad D, Emdin C, Kiran A, Anderson S, Callender T, Emberson J . Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022):957-967. DOI: 10.1016/S0140-6736(15)01225-8. View

Hollander W . Role of hypertension in atherosclerosis and cardiovascular disease. Am J Cardiol. 1976; 38(6):786-800. DOI: 10.1016/0002-9149(76)90357-x. View

Rubattu S, Pagliaro B, Pierelli G, Santolamazza C, Di Castro S, Mennuni S . Pathogenesis of target organ damage in hypertension: role of mitochondrial oxidative stress. Int J Mol Sci. 2015; 16(1):823-39. PMC: 4307277. DOI: 10.3390/ijms16010823. View

10.

Schmieder R . End organ damage in hypertension. Dtsch Arztebl Int. 2010; 107(49):866-73. PMC: 3011179. DOI: 10.3238/arztebl.2010.0866. View

11.

Singh R, Mengi S, Xu Y, Arneja A, Dhalla N . Pathogenesis of atherosclerosis: A multifactorial process. Exp Clin Cardiol. 2009; 7(1):40-53. PMC: 2716189. View

12.

Zaromytidou M, Siasos G, Coskun A, Lucier M, Antoniadis A, Papafaklis M . Intravascular hemodynamics and coronary artery disease: New insights and clinical implications. Hellenic J Cardiol. 2016; 57(6):389-400. DOI: 10.1016/j.hjc.2016.11.019. View

13.

Fishman A . Endothelium: a distributed organ of diverse capabilities. Ann N Y Acad Sci. 1982; 401:1-8. DOI: 10.1111/j.1749-6632.1982.tb25702.x. View

14.

Cahill P, Redmond E . Vascular endothelium - Gatekeeper of vessel health. Atherosclerosis. 2016; 248:97-109. PMC: 6478391. DOI: 10.1016/j.atherosclerosis.2016.03.007. View

15.

Della Rocca D, Pepine C . Endothelium as a predictor of adverse outcomes. Clin Cardiol. 2010; 33(12):730-2. PMC: 6653703. DOI: 10.1002/clc.20854. View

16.

Dharmashankar K, Widlansky M . Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep. 2010; 12(6):448-55. PMC: 2982873. DOI: 10.1007/s11906-010-0150-2. View

17.

Gkaliagkousi E, Douma S, Zamboulis C, Ferro A . Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension. J Hypertens. 2009; 27(12):2310-20. DOI: 10.1097/HJH.0b013e328330e89a. View

18.

Gkaliagkousi E, Passacquale G, Douma S, Zamboulis C, Ferro A . Platelet activation in essential hypertension: implications for antiplatelet treatment. Am J Hypertens. 2010; 23(3):229-36. DOI: 10.1038/ajh.2009.247. View

19.

Flammer A, Anderson T, Celermajer D, Creager M, Deanfield J, Ganz P . The assessment of endothelial function: from research into clinical practice. Circulation. 2012; 126(6):753-67. PMC: 3427943. DOI: 10.1161/CIRCULATIONAHA.112.093245. View

20.

Celermajer D, Sorensen K, Gooch V, Spiegelhalter D, Miller O, Sullivan I . Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340(8828):1111-5. DOI: 10.1016/0140-6736(92)93147-f. View

21.

Muiesan M, Salvetti M, Monteduro C, Corbellini C, Guelfi D, Rizzoni D . Flow-mediated dilatation of the brachial artery and left ventricular geometry in hypertensive patients. J Hypertens. 2001; 19(3 Pt 2):641-7. DOI: 10.1097/00004872-200103001-00018. View